Kyobo Life to sell maiden won-denominated hybrid bond next month Hybrid bond sale likely to help improve insurer's financial structure
Translated by Kim So-in 공개 2021-08-23 08:13:42
이 기사는 2021년 08월 20일 08:01 thebell 에 표출된 기사입니다.
Kyobo Life Insurance plans to raise as much as 500 billion won ($425 million) from its maiden won-denominated hybrid bond sale to improve its financial structure.Kyobo Life and its bookrunners, KB Securities and Korea Investment & Securities, are preparing to issue a hybrid bond to secure liquidity, industry sources said on Wednesday. The issuer is expected to start a book building process and issue the bond in mid-September.
The issuer has tentatively decided to raise 300 billion won through the issuance. The amount could be increased to 500 billion won if the bond is oversubscribed during the book building process in early September.
This will be the life insurer’s first offering of a hybrid bond, which is regarded as an asset, instead of debt, in financial statements.
Kyobo Life has issued mezzanine debts whenever it needed to secure liquidity and improve the financial structure. In July 2017, the life insurer raised about $500 million in its offering of a foreign currency-denominated hybrid bond. It was the first time a domestic life insurer sold a hybrid bond in the Korean paper market. Korean paper refers to foreign currency debt issued by South Korean entities abroad. The bond was underwritten by Citigroup Global Markets Korea Securities, JP Morgan, Nomura Securities, and UBS.
Kyobo Life plans to use the proceeds from the issuance to repay borrowings and increase its capital base, as its total capital decreased from 12.9 trillion won on a consolidated basis at the end of last year to 11.9 trillion won at the end of June this year. (Reporting by Chul Kang)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [클리니컬 리포트]박셀바이오, '가보지 않은' NK 췌장암 임상 '숨고르기'
- [제일약품의 온코닉테라퓨틱스 첫 '신약']'비상장 바이오벤처' 국산신약, 블록버스터에 도전장
- [Red & Blue]보라티알, 오염수 방류 중단되자 '소금 테마' 주도
- 초격차 저력 삼성바이오로직스 실적 '또 자체기록 경신'
- [Company Watch]'손바뀜 실패' 프리엠스, 매각 완주 가능성은
- [코스닥 MZ 리더가 온다]지배구조 재편 성공한 강원에너지, 성장 발판 마련
- [한경협 파이낸셜 리포트]'돈 굴리기' 보수적 접근, '채권 투자' 집중
- 콤텍시스템, 'BM 금융 솔루션 데이' 개최
- OTT 티빙, 마케팅담당 임원 '컬리→배민 출신'으로
- [보험경영분석]ABL생명, 투자부문 금리효과에 흑자…진짜는 '회계효과'